Quantcast

Latest Access Pharmaceuticals Inc. Stories

2010-11-09 07:30:00

DALLAS and NEW YORK, Nov. 9, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that its Chairman, Steven Rouhandeh, will present at the 1st Annual LifeTech Capital Miami Medical Investors Conference on Friday, November 12, 2010, at 1:00 pm ET. The conference is being held at the JW...

2010-11-03 07:00:00

DALLAS and NEW YORK, Nov. 3, 2010 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has commenced a Phase 2 combination trial for its second generation DACH-platinum cancer drug, ProLindac, in platinum-sensitive ovarian-cancer patients. This trial is an open-label, Phase 2 study of...

2010-11-01 13:59:00

DALLAS and NEW YORK, Nov. 1, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has been awarded $1.5 million in government grants. Under the recently enacted Patient Protection and Affordable Care Act, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed...

2010-10-27 07:00:00

DALLAS and NEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into a pre-licensing feasibility agreement with a leading biopharmaceutical company to develop an oral formulation of an undisclosed prostate cancer compound utilizing its proprietary vitamin...

2010-10-20 07:00:00

DALLAS and NEW YORK, Oct. 20 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the...

2010-10-15 07:00:00

DALLAS and NEW YORK, Oct. 15 /PRNewswire/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard - an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. In addition, the Company has received reimbursement for...

2010-10-11 07:00:00

DALLAS and NEW YORK, Oct. 11 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy. Some of the findings reported in the ESMO presentation included: MuGard provided a significant improvement and/or...

2010-09-29 07:30:00

DALLAS and NEW YORK, Sept. 29 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies. As a result of the continued advancements made with its Cobalamin program, Access rebranded...

2010-09-21 07:30:00

DALLAS and NEW YORK, Sept. 21 /PRNewswire/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories....

2010-09-15 07:30:00

DALLAS and NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information. "We are proud to have launched our product website...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related